PADER (Periodic Adverse Drug Experience Report)
Last reviewedA Periodic Adverse Drug Experience Report (PADER) is the post-marketing periodic safety report that holders of approved US drug applications submit to the FDA. It is required quarterly for the first three years after approval and annually after that.
Key facts
| Regulation | 21 CFR 314.80(c)(2) |
|---|---|
| Frequency | Quarterly for three years from approval, then annually |
| Due | Within 30 days of the close of the quarter; within 60 days of the anniversary date for annual reports |
| For biologics | Periodic Adverse Experience Report (PAER), 21 CFR 600.80 |
| Alternative | The FDA accepts a PBRER in place of the PADER only under a waiver (21 CFR 314.90); its reporting-frequency requirements generally still apply |
What a PADER contains
Each report contains a narrative summary and analysis, an analysis of the 15-day Alert reports submitted during the interval, a history of actions taken since the last report because of adverse drug experiences (for example, labeling changes or studies initiated), an index line listing, and individual case safety reports for every adverse drug experience not already reported as a 15-day Alert report.
Sources
Read more
Part of our guide to Pharmacovigilance Aggregate Reports: DSUR, PBRER, PSUR and PADER

